This article is more than 5 years old. Information may no longer be current.

EyeGate files to initiate Ocular Bandage Gel pilot study

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharmaceuticals has filed a protocol with the FDA to initiate a pilot study of its Ocular Bandage Gel eye drop for the treatment of punctate epitheliopathies, the company announced in a press release.

The FDA will take 30 days to review the filing and then will allow the study to start or provide comments to be addressed, the release said.

“This is potentially a large opportunity, as OBG would be the only eye drop treatment available for the millions of patients in the U.S. with [punctate epitheliopathies] and tear film instability,” EyeGate CEO Stephen From said in the release. “We continue to explore new uses for our [hyaluronic acid] polymer and believe that its unique cross-linked capabilities will better serve patients who suffer from ocular surface pathologies and corneal injuries.”